SCHEMBL5494597

SCHEMBL5494597

Oc1ccc(-c2nc(-c3cccnc3Cl)no2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.61
NPC1 O15118 8/20 0.61
PKM P14618 6/20 0.61
MAPT P10636 4/20 0.61
HSD17B10 Q99714 3/20 0.61
NFKB1 P19838 1/20 0.61
NFKB2 Q00653 1/20 0.61
RELA Q04206 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
RAB9A P51151 9/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C19 P33261 1/20 0.50
TP53 P04637 8/20 0.46
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HPGD P15428 2/20 0.46
BCHE P06276 1/20 0.46
ACHE P22303 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22230633 0.79 DHODH (0.47) SMN1; SMN2NPC1PKMMAPTRAB9A
SCHEMBL5501327 0.79 S1PR1 (0.63) SMN1; SMN2NPC1PKMMAPTHSD17B10
SCHEMBL5498744 0.77 RAB9A (0.49) SMN1; SMN2NPC1PKMMAPTNFKB1
SCHEMBL26095552 0.74 NR1H4 (0.70) SMN1; SMN2NPC1PKMMAPTHSD17B10
SCHEMBL16481889 0.73 L3MBTL1 (0.47) SMN1; SMN2NPC1PKMMAPTHSD17B10
SCHEMBL2062609 0.73 NR1H4 (0.78) SMN1; SMN2NPC1PKMMAPTHSD17B10
SCHEMBL3061782 0.73 NR1H4 (0.78) SMN1; SMN2NPC1PKMMAPTHSD17B10
SCHEMBL3074852 0.71 RAB9A (0.58) SMN1; SMN2NPC1PKMMAPTNPSR1
SCHEMBL3736895 0.71 NPC1 (0.72) SMN1; SMN2NPC1MAPTHSD17B10NFKB1
SCHEMBL1250919 0.71 SMN1; SMN2 (0.73) SMN1; SMN2NPC1PKMMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1625123-A4 3-(2-AMINO-1-AZACYCLYL)-5-ARYL-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS MERCK & CO INC (US) 2007-08-29 EP disclosed
US-20060252741-A1 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists MERCK & CO., INC. 2006-11-09 US disclosed
CN-1788008-A 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists MERCK & CO INC (US) 2006-06-14 CN disclosed
EP-1625123-A2 3-(2-AMINO-1-AZACYCLYL)-5-ARYL-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS Merck & Co., Inc. (US) 2006-02-15 EP disclosed
WO-2004103279-A2 3-(2-AMINO-1-AZACYCLYL)-5-ARYL-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS MERCK & CO., INC. (US) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252741-A1 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists S1PR1, S1PR3, S1PR5 SMN1; SMN2 2125/4885NPC1 963/4885PKM 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.